GST Exemption Announced for Cancer Treatment Gene Therapy

AIIMS Develops Affordable CAR-T Cell Therapy for Multiple Myeloma

Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

FDA Approves BRAFTOVI® Combination Regimen as First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

The Role of Big Data in Precision Medicine

Caris Life Sciences Celebrates 1,000+ Precision Medicine Studies, Advancing Cancer Research and Patient Outcomes

OncoHelix and Qualisure Diagnostics Partner to Bring Thyroid GuidePx® Test to Canadian Patients

Gates Foundation Invests $50 Million in Tessera Therapeutics to Advance Gene Therapy for Sickle Cell Disease

FDA Approves Ensartinib (Ensacove) as First-Line Treatment for ALK-Positive NSCLC

Guardant Health and Boehringer Ingelheim Collaborate to Advance Liquid Biopsy CDx for HER2-Targeted Therapy in NSCLC

Cartherics Receives $300K G-Rex Grant to Advance Cancer Cell Therapy Manufacturing

Roche Revolutionizes Mass Spectrometry Diagnostics with Launch of cobas® Mass Spec Solution

Complete Genomics Partners with Eurofins Clinical Enterprise to Expand Sequencing Service Offerings

Home
/
update
/
details

Complete Genomics Partners with Eurofins Clinical Enterprise to Expand Sequencing Service Offerings

NextEdge Admin

18 Dec 2024

1 min 51 sec

Eurofins Clinical Enterprise,sequencing platforms,DNBSEQ™

Complete Genomics, a San Jose-based genomics tools manufacturer, has announced Eurofins Clinical Enterprise, LLC, headquartered in Framingham, Massachusetts, as the latest member of its Sequencing Service Provider Program. This program connects customers to a network of service providers utilizing Complete Genomics’ DNBSEQ™ sequencing platforms for high-quality sequencing services.

Through this partnership, Eurofins Clinical Enterprise will leverage the DNBSEQ-T7RS™ (“T7”), Complete Genomics’ flagship sequencer, to perform whole genome sequencing, low-pass whole genome sequencing, spatial-resolved transcriptomics, and single-cell sequencing. This collaboration aims to enhance Eurofins’ flexibility in managing diverse project sizes while maintaining competitive pricing and rapid turnaround times.

“This partnership reflects our commitment to expanding possibilities while reducing costs and turnaround times for customers,” said Rob Tarbox, VP of Product and Marketing at Complete Genomics.

Complete Genomics, established in 2005, specializes in high-throughput, cost-effective DNA sequencing solutions, supporting over 9,400 publications across diverse applications.

Eurofins Clinical Enterprise, a CLIA-certified, CAP-accredited, NY CLEP-licensed laboratory, offers customizable multiomic testing solutions for academic research, biopharma, clinical studies, and lifestyle genomics. Part of Eurofins Scientific, a global leader in testing services, it aims to advance discovery and innovation.